Biopharma gains a seamless transition from drug discovery
through drug product manufacturing
SAN DIEGO, June 20, 2024 /PRNewswire/ -- Abzena, the leading
end-to-end integrated contract and development manufacturing
organization (CDMO) for complex biologics and bioconjugates, and
Argonaut Manufacturing Services, Inc., a cGMP CDMO serving the
biopharmaceutical and diagnostics industries, announced a strategic
partnership to provide a fully integrated drug substance and drug
product manufacturing solution for biopharmaceutical organizations.
This alliance offers a streamlined approach for customers looking
to rapidly progress therapies into the clinic, or onward into
later-stage commercial manufacturing.
The partnership removes the white space in drug development for
biopharma drug companies by utilizing a single development and
manufacturing team to seamlessly transition from early discovery
services (ranging from antibody engineering, developability,
formulation development, cell line development, process and
analytical development) through clinical and commercial
manufacturing of drug substance and drug product. This tight
integration of activities facilitates more informed and rapid
decision-making, efficient technology transfer, and a reduction in
supply chain complexity.
Both Abzena and Argonaut have extensive experience in developing
and manufacturing biopharmaceutical programs that span the entire
development pathway. By harmonizing Abzena's comprehensive antibody
discovery, development and cGMP manufacturing capabilities with
Argonaut's exemplary sterile fill-finish offering, encapsulates a
full-spectrum service model designed to optimize efficiency and
accelerate development timelines.
Matt Stober, CEO of Abzena said,
"Abzena's mission is to rapidly move medicines forward to patients
in need. Embarking on this strategic partnership with Argonaut
further demonstrates our commitment to this mission, marking a
significant milestone in our quest to provide streamlined solutions
that address the unique needs of our customers. This collaboration
signifies a pivotal advancement in biopharmaceutical development
and reinforces the shared vision of both our organizations to drive
innovation, quality, and speed to market for our customer's
life-changing treatments.
Wayne Woodard, CEO of Argonaut
said, "For the past few years, Argonaut and Abzena have been
successfully building and strengthening their partnership. Today,
we further enhance this collaboration by publicly recognizing the
value that our two companies can generate for our clients.
Ecosystems are an integral part of our business, and these
partnerships are crucial in providing comprehensive support to all
our clients, regardless of their size, to ensure efficient and
successful delivery of their drugs to patients."
About Abzena
Abzena is the leading end-to-end bioconjugate and complex
biologics CDMO + CRO. From discovery through commercial launch, we
support customers with fully integrated programs or individual
services designed to de-risk and streamline the development of new
treatments for patients in need. With the ability to tailor its
strategy and customer experience to each project, Abzena develops
and implements innovative solutions that enable biotech and
biopharma companies to realize the full potential of their molecule
and move medicines forward faster. The company has research,
development, and cGMP facilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK. Abzena is owned by Welsh,
Carson, Anderson & Stowe, one of the world's leading private
equity investors. Learn more at abzena.com.
About Argonaut Manufacturing Services, Inc.
Argonaut Manufacturing Services, Inc. is an FDA-registered cGMP
contract manufacturing organization (CMO) dedicated to providing
custom manufacturing and supply chain solutions for
biopharmaceutical and diagnostic companies. Aseptic drug
fill/finish features state-of-the-art automated equipment for
high-yield filling of sterile injectable drugs including biologics,
peptides, small molecules, and vaccines. Diagnostic manufacturing
includes proprietary lyophilization technology and a spectrum
of kitting capabilities. Projects are supported with full
analytical quality control services including warehousing and
global shipping logistics. Serving innovators in the life science,
molecular diagnostics, and biopharma industries, Argonaut provides
a wide range of flexible solutions for diverse outsourcing
needs.
View original
content:https://www.prnewswire.co.uk/news-releases/abzena-and-argonaut-partner-to-offer-accelerated-end-to-end-drug-development-support-for-biopharmaceutical-companies-302178128.html